







Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-03043-1>,
published online 25 May 2024

<https://doi.org/10.1038/s41591-024-03156-7>

Published online: 3 July 2024

Glenn M. Chertow , Anna Marie Chang, G. Michael Felker, Mark Heise ,
Elena Velkoska, Bengt Fellström, David M. Charytan, Regina Clementi,
C. Michael Gibson , Shaun G. Goodman, Meg Jardine, Adeera Levin ,
Yuliya Lokhnygina, Jenny Mears, Roxana Mehran, Peter Stenvinkel ,
Angela Yee-Moon Wang , David C. Wheeler, Carmine Zoccali ,
Paul M. Ridker, Kenneth W. Mahaffey, Pierluigi Tricoci & Myles Wolf 

In the version of the article initially published, Angela Yee-Moon Wang's name appeared incorrectly (as Angela Wang) and has now been amended in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-023-02275-x>,
published online 3 April 2023

<https://doi.org/10.1038/s41591-024-03161-w>

Published online: 2 July 2024

Nabil F. Saba , Conor E. Steuer, Asari Ekpenyong , Ashley McCook-Veal ,
Kelly Magliocca, Mihir Patel, Nicole C. Schmitt , William Stokes ,
James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald ,
Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah,
Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen,
Dong M. Shin, Yong Teng & Christine H. Chung 

In the version of the article initially published, in the "Toxicity analysis" section, "Nine patients (25%) discontinued all therapy as a result of AEs" has been corrected to "Five patients (13.8%)...". In the fifth paragraph of the Discussion, "9 patients (25%) discontinued therapy as a result of AEs" has been removed and "25%" has been changed to "13.8%" in the text "Of note is a higher rate of AE-related treatment discontinuation of 13.8%". These changes have been made to the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024,
corrected publication 2024